PharmaCielo Ltd. PCLO PCLOF the Canadian parent of Colombia's cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced its financial results on Wednesday for the third quarter ended Sept. 30, 2023.
The company narrowed its net loss and selling, general and administrative expenses significantly year-over-year as well as an adjusted EBITDA loss, the report showed.
“Our team has built a focused and lean organization over the past twelve months, and effectively re-positioned the product portfolio on higher margin products,” Marc Lustig, chairman and CEO said. “With total SG&A expenses down over 40% from Q3 of last year, and no meaningful capital expenditures necessary to get to full commercial scale, we are even better placed to generate higher profitability and cash flows as our sales efforts pay off."
Q3 2023 Financial Results
- Total revenue amounted to CA$351,688 ($258,777), down from CA$475,323 in the prior year’s period.
- Gross loss totaled CA$349,187, up from $305,850 gross loss in the same quarter of 2022.
- Total selling, general, and administrative expenses amounted to roughly CA$2 million, down from CA$3.4 million in the corresponding period of last year.
- Net loss for the period totaled CA$2.8 million, down from CA$5.2 million in the prior year’s period.
- Adjusted EBITDA came in negative at CA$1.4 million, compared to a negative adjusted EBITDA of CA2.4 million in the third quarter of 2022.
- As of Sept. 30, 2023, total assets amounted to CA26.6 million and total liabilities were CA$23.8 million, compared to CA$25.1 million and CA$18.7 million, respectively on Dec. 31, 2022.
PCLOF Price Action
PharmaCielo’s shares traded 6.8453% lower at $0.1311 per share after the market close on Tuesday afternoon.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.
Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!
Just this year, the PotProfits portfolio has seen smoking-hot gains like:
- 47.10% with $GTBIF
- 40.23% with $TCNNF
- 21.50% with $VFF
Related News
- PharmaCielo Q2 2023 Results: Revenue Drops But CEO Is Optimistic About Future Growth
- PharmaCielo Q1 2023: Revenue Down 34.2% YoY, CEO Expects Robust Global Sales Of Cannabis Flower In 2023
- PharmaCielo FY 2022 Revenue Grows 173%, What About Adjusted EBITDA?
Photo: Courtesy of Elsa Olofsson on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!